Project description:In this work the genomic expression of two Burkholderia cenocepacia clonal variants (IST439 and IST4113) were compared. These isolates were collected from a chronically colonized cystic-fibrosis patient that has died from the cepacia syndrome. IST439 was the first B. cenocepacia isolate recovered from the patient and it is thought to have initiated the infection while the IST4113 isolate was recovered three years later, after a period of exacerbated infection that compelled the patient to hospitalization and intravenous therapy with gentamicine and ceftazidime. Among other phenotypic differences, IST4113 is much more resistant to a wide range of antimicrobials tested with very different biological targets
Project description:Derived from coenzyme A degradation in mammalian cells, the aminothiol cysteamine may represent a promising new adjunct treatment for pulmonary exacerbations in cystic fibrosis (CF). This experiment aims to characterise the effect of sub-MIC cysteamine on Burkholderia cenocepacia J2315. Samples were cultured in SCFM2 (triplicate), and exposed to either cysteamine or a H2O control.
Project description:Using a discovery shotgun proteomics approach, the expressed proteome of Burkholderia cenocepacia (strain H111) was analyzed under normal and starved nitrogen growth conditions. B. cenocepacia is an opportunistic human pathogen that is particularly problematic for patients suffering from cystic fibrosis.
Project description:Burkholderia cenocepacia sequence type 32 (ST32) represents one of the most globally distributed strains from Bukrholderia cepacia complex (Bcc), which infected 30% of Czech cystic fibrosis (CF) patients. The aim of this study was to compare gene expression in two pairs of ST32 clinical isolates that were subjected to cultivation in two different conditions, characteristic for chronic B. cenocepacia infection in CF patients. ST32 strain is known to be a problematic epidemic strain, which caused a serious outbreak at the Prague CF centre.
Project description:Fang2011 - Genome-scale metabolic network of
Burkholderia cenocepacia (iKF1028)
This model is described in the article:
Exploring the metabolic
network of the epidemic pathogen Burkholderia cenocepacia J2315
via genome-scale reconstruction.
Fang K, Zhao H, Sun C, Lam CM, Chang
S, Zhang K, Panda G, Godinho M, Martins dos Santos VA, Wang
J.
BMC Syst Biol 2011; 5: 83
Abstract:
BACKGROUND: Burkholderia cenocepacia is a threatening
nosocomial epidemic pathogen in patients with cystic fibrosis
(CF) or a compromised immune system. Its high level of
antibiotic resistance is an increasing concern in treatments
against its infection. Strain B. cenocepacia J2315 is the most
infectious isolate from CF patients. There is a strong demand
to reconstruct a genome-scale metabolic network of B.
cenocepacia J2315 to systematically analyze its metabolic
capabilities and its virulence traits, and to search for
potential clinical therapy targets. RESULTS: We reconstructed
the genome-scale metabolic network of B. cenocepacia J2315. An
iterative reconstruction process led to the establishment of a
robust model, iKF1028, which accounts for 1,028 genes, 859
internal reactions, and 834 metabolites. The model iKF1028
captures important metabolic capabilities of B. cenocepacia
J2315 with a particular focus on the biosyntheses of key
metabolic virulence factors to assist in understanding the
mechanism of disease infection and identifying potential drug
targets. The model was tested through BIOLOG assays. Based on
the model, the genome annotation of B. cenocepacia J2315 was
refined and 24 genes were properly re-annotated. Gene and
enzyme essentiality were analyzed to provide further insights
into the genome function and architecture. A total of 45
essential enzymes were identified as potential therapeutic
targets. CONCLUSIONS: As the first genome-scale metabolic
network of B. cenocepacia J2315, iKF1028 allows a systematic
study of the metabolic properties of B. cenocepacia and its key
metabolic virulence factors affecting the CF community. The
model can be used as a discovery tool to design novel drugs
against diseases caused by this notorious pathogen.
This model is hosted on
BioModels Database
and identified by:
MODEL1507180051.
To cite BioModels Database, please use:
BioModels Database:
An enhanced, curated and annotated resource for published
quantitative kinetic models.
To the extent possible under law, all copyright and related or
neighbouring rights to this encoded model have been dedicated to
the public domain worldwide. Please refer to
CC0
Public Domain Dedication for more information.
Project description:Burkholderia cenocepacia J2315 belongs to the ET12 lineage which has caused outbreaks among cystic fibrosis patients worldwide. Strains belonging to the ET12 lineage are characterized by the presence of the “Burkholderia cepacia epidemic strain marker” (BCESM). This marker is located on a genomic island involved in virulence, but the exact function of many genes in the BCESM region remains unknown. In the present study we investigated the function of three of these genes (BCAM0257, BCAM0258 and BCAM0259). We created overexpression mutants and performed a transcriptome analysis of the toxin (BCAM0258) overexpression mutant.
Project description:Burkholderia cepacia complex (Bcc) comprises opportunistic bacteria infecting hosts such as cystic fibrosis (CF) patients. Bcc long-term infection of CF patient airways has been associated with emergence of phenotypic variation. Here we studied two Burkholderia multivorans clonal isolates (D2095 and D2214) displaying different morphotypes from a chronically infected CF patient in order to evaluate traits development during lung infection.
Project description:The gene expression of the opportunictic cystic fibrosis lung pathogen Burkholderia multivorans ATCC 17616 was investigated under different growth conditions relevant for growth in the cystic fibrosis lung.
Project description:The gene expression of the opportunictic cystic fibrosis lung pathogen Burkholderia multivorans ATCC 17616 was investigated under different growth conditions relevant for growth in the cystic fibrosis lung.